Document Report Card

Basic Information

ID: ALA4619798

Journal: ACS Med Chem Lett

Title: Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study.

Authors: Yan VC, Yang KL, Ballato ES, Khadka S, Shrestha P, Arthur K, Georgiou DK, Washington M, Tran T, Poral AH, Pham CD, Yan MJ, Muller FL.

Abstract: Glycolysis inhibition remains aspirational in cancer therapy. We recently described a promising phosphonate inhibitor of enolase for cancers harboring homozygous deletions of ENO1. Here, we describe the application of a nitroheterocycle phosphonoamidate pro-drug pair to capitalize on tumor hypoxia. This bioreducible prodrug exhibits greater-than 2-fold potency under hypoxic conditions compared to normoxia and exhibits robust stability in biological fluids. Our work provides strong in vitro proof-of-concept for using bioreduction as a pro-drug delivery strategy in the context of enolase inhibition.

CiteXplore: 32676158

DOI: 10.1021/acsmedchemlett.0c00203